ChemoCentryx Inc. (NASDAQ:CCXI) went up by 108.30% from its latest closing price compared to the recent 1-year high of $42.16. The company’s stock price has collected 0.67% of gains in the last five trading sessions. The Wall Street Journal reported 2 hours ago that Amgen to Buy ChemoCentryx for $3.7 Billion
Is It Worth Investing in ChemoCentryx Inc. (NASDAQ :CCXI) Right Now?
Plus, the 36-month beta value for CCXI is at 1.69.
The average price from analysts is $71.25, which is $26.35 above the current price. CCXI currently public float of 60.97M and currently shorts hold a 10.76% ratio of that float. Today, the average trading volume of CCXI was 1.35M shares.
CCXI’s Market Performance
CCXI stocks went up by 0.67% for the week, with a monthly drop of -10.20% and a quarterly performance of 36.37%, while its annual performance rate touched 59.56%. The volatility ratio for the week stands at 6.29% while the volatility levels for the past 30 days are set at 5.80% for ChemoCentryx Inc. The simple moving average for the period of the last 20 days is 115.86% for CCXI stocks with a simple moving average of 79.92% for the last 200 days.
Analysts’ Opinion of CCXI
Many brokerage firms have already submitted their reports for CCXI stocks, with Canaccord Genuity repeating the rating for CCXI by listing it as a “Buy.” The predicted price for CCXI in the upcoming period, according to Canaccord Genuity is $81 based on the research report published on August 04th of the current year 2022.
SVB Leerink, on the other hand, stated in their research note that they expect to see CCXI reach a price target of $64. The rating they have provided for CCXI stocks is “Outperform” according to the report published on October 11th, 2021.
JP Morgan gave a rating of “Neutral” to CCXI, setting the target price at $38 in the report published on October 11th of the previous year.
CCXI Trading at 109.37% from the 50-Day Moving Average
After a stumble in the market that brought CCXI to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 19.12% of gains for the given period.
Volatility was left at 5.80%, however, over the last 30 days, the volatility rate increased by 6.29%, as shares surge +100.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +124.98% upper at present.
During the last 5 trading sessions, CCXI rose by +116.55%, which changed the moving average for the period of 200-days by +55.12% in comparison to the 20-day moving average, which settled at $24.52. In addition, ChemoCentryx Inc. saw -33.78% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CCXI starting from Tyree James L, who sale 3,863 shares at the price of $25.66 back on Jun 09. After this action, Tyree James L now owns 19,138 shares of ChemoCentryx Inc., valued at $99,129 using the latest closing price.
Tyree James L, the Director of ChemoCentryx Inc., sale 37,500 shares at $35.02 during a trade that took place back on Dec 17, which means that Tyree James L is holding 15,275 shares at $1,313,165 based on the most recent closing price.
Stock Fundamentals for CCXI
Current profitability levels for the company are sitting at:
- -408.29 for the present operating margin
- +84.25 for the gross margin
The net margin for ChemoCentryx Inc. stands at -413.03. Equity return is now at value -47.20, with -31.50 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.27.